Free Newsletter
Juvaris completes $25M close of series B
Adjuvant vaccines developer Juvaris BioTherapeutics has completed the first close of a Series B round. The Burlingame, CA-based company says it will use the capital to advance its technology platform and carry its lead adjuvant, JVRS-100, into midstage clinical development for seasonal and pandemic flu.
The financing of up to $25 million was funded by SV Life Sciences and Kleiner Perkins Caufield & Byers (KPCB). SV Life Sciences' managing partner Michael Ross will join Juvaris Board of Directors. "Mike's highly successful drug development experience at Genentech and track record of building strong biotech companies at SVLS will be of critical ongoing value to Juvaris," said CEO Grant Pickering.
- here's the Juvaris release
Related Articles:
Juvaris strikes collaboration deal on new vaccines
Vaccine market trends, 2009 predictions
Emerging Drug Developer: Juvaris BioTherapeutics
More stories about Juvaris BioTherapeutics
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: